Article Details
Retrieved on: 2025-04-14 17:36:17
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Atsena Therapeutics' advancements in regenerative medicine through gene therapy, focusing on rare diseases like XLRS and LCA1. Their recent $150 million funding highlights efforts in drug discovery and clinical trials under FDA designations, supported by key investors like the Foundation Fighting Blindness.
Article found on: pulse2.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here